Sexually Transmitted Diseases (STDs) are also known as Venereal diseases (VDs) or Sexually Transmitted Infections (STIs). A variety of methods have been employed for diagnosis of STDs that differ based on the type of disease. The objective of this report is to provide an in-depth understanding of diagnostic tests of STDs. The market diagnostic testing of STDs was valued at $96.7 billion in 2013 with a corresponding test volume of 4,204 million. Rising incidences of fatal STDs, corresponding high-economic burden and consequent implementation of Provider-Initiated Counselling and Testing (PICT) and Client-Initiated Counselling and Testing (CICT) drive the growth of STD testing market; however, inadequate infrastructure provisions such as labs, equipment and supplies, lack of trained laboratory personnel in the secluded geographic locations (for example, West African countries) and stigma associated with voluntary testing are likely to be the major restraints of the market. However, global initiatives along with development in healthcare infrastructure will provide future growth thrust for the market. Thus, the diagnostic testing of STDs is estimated to grow at a CAGR of 8.5% over the forecast period 2014-2020 to reach market size of $167.4 billion in 2020. The test volume will rise to 5,520 million in 2020.
The global market for diagnostic testing of STDs is segmented based on types of STDs – Chlamydia testing, Gonorrhoea testing, Syphilis testing, Human Immunodeficiency Virus (HIV) testing, Herpes Simplex Virus (HSV) testing, Human Papilloma Virus (HPV) testing and Chancroid testing. HIV testing, which is the third largest STD testing market, would grow at a CAGR of 10.9% during 2014 – 2020.
Based on point of testing, market is segmented in to laboratories and point-of-care (PoC). Currently, laboratories perform bulk of the tests and would continue to hold larger share of the market, both in terms of volume and revenue. PoCs will grow at constant rate during the forecast period.
The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at fastest rate.
As elaborated earlier, many healthcare institutions provide diagnostic testing services for STDs, such as specialized STD clinics, Genito-Urinary Medicine (GUM) clinics along with general hospitals, government laboratories and private diagnostic centres. The afore-mentioned thus constitute key market participants of the global diagnostic testing of STDs market. Along with the testing service providers, many companies provide devices such as laboratory instruments and POC testing kits/devices for STDs; for instance, Roche Holdings AG. Roche Holdings AG recently announced an immunoassay diagnostic test for the detection of Syphilis during a routine clinical practice. Other companies profiled in the report are BioMerieux, Hologic Inc., Becton Dickinson & Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.
KEY BENEFITS
The analysis helps in understanding the strategies adopted by various companies for gaining market share in the market for diagnostic testing of STDs
The report provides comprehensive analysis of factors that drive and restrict the growth of the market for diagnostic testing of STDs.
Market conditions of STD diagnostic testing market across all geographic regions are comprehensively analyzed. Key trends such as national and voluntary screening programs within regional markets, for example, European markets are expected to drive growth of the market.
Prime focus of the report is opportunity-analysis within this market. STD infected individuals refrain from testing in specialized STD clinics and Genito-Urinary Medicine (GUM) clinics due to the associated social stigma. Such change in the consumer buying behavior would prove to be an opportunity and be beneficial for public and private labs.
MARKET SEGMENTATION
The diagnostic testing of STDs market is segmented into types of STDs tested, testing devices, laboratory testing, PoC testing and geography.
MARKET BY SEXUALLY TRANSMITTED DISEASE TYPES
Chlamydia testing
Syphilis testing
Gonorrhoea testing
Herpes Simplex Virus testing
Human Papilloma Virus testing
Human Immunodeficiency Virus testing
Chancroid testing
MARKET BY LOCATION OF TESTING
Laboratory Testing
Commercial/Private labs
Public Health Labs
Point of Care (PoC) testing
MARKET BY TESTING DEVICES
Laboratory Devices: Instruments and systems
Thermal Cyclers - PCR
Lateral Flow Readers - Immunochromatographic assays
Flow Cytometers
Differential Light Scattering machines
Absorbance microplate reader - Enzyme Linked Immunosorbent Assay (ELISA)
POC testing Devices: Various diagnostic kits
Phone chips (microfluidics + ICT)
Portable / bench top / rapid diagnostic kits
MARKET BY GEOGRAPHY
North America
Europe
Asia-Pacific
Latin America, Middle East, Africa (LAMEA)
TABLE OF CONTENTS
1 INTRODUCTION
1.1 Report Description
1.2 Reason for doing the study
1.3 Key Benefits
1.4 Key Market Segments
1.5 Key Audiences
1.6 Research Methodology
1.6.1 Secondary Research
1.6.2 Primary Research
1.6.3 Analyst tools and models
2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond what to expect by 2025 ($ Million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Upcoming trends for venereal diseases diagnostic testing market
3.3 Technological Advancements for venereal diseases diagnostic testing market
3.4 Emerging economies as a beneficial criterion for the investors
3.5 Key Findings
3.5.1 Top Factors Impacting for venereal diseases diagnostic testing market
3.5.2 Top Investment Pockets for venereal diseases diagnostic testing market
3.5.3 Top winning strategies for venereal diseases diagnostic testing market
3.6 Government Regulations and reimbursement
3.7 Value chain analysis
3.8 Market Share Analysis, 2013
3.9 Market Dynamics
3.9.1 Drivers
3.9.2 Restraints
3.9.3 Opportunities
4 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY DISEASE TYPE
4.1 Chlamydia testing (volume and value)
4.2 P&S Syphilis testing (volume and value)
4.3 Gonorrhea testing (volume and value)
4.4 Herpes Simplex Virus (HSV) testing (volume and value)
4.5 Human Papilloma Virus (HPV) testing (volume and value)
4.6 Human Immunodeficiency Virus (HIV) testing (volume and value)
4.7 Chancroid testing (volume and value)
5 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY LOCATION OF TESTING
5.1 Laboratory testing
5.1.1 Key market trends
5.1.2 Key growth factors and opportunities
5.1.3 Market size and forecast
5.1.4 Commercial laboratory testing
5.1.5 Private laboratory testing
5.1.6 Public laboratory testing
5.2 POC testing
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
6 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY TESTING DEVICES
6.1 Laboratory Testing Devices
6.1.1 PCRs
6.1.2 Immunochromatographic capillary flow dipstick technology (Assay)
6.1.3 Flow Cytometers
6.1.4 Differential Light Scattering
6.1.5 Enzyme Linked Immunosorbent Assay (ELISA)
6.2 POC Testing Devices
6.2.1 Phone chips (microfluidics + ICT)
6.2.2 Portable / bench top / rapid diagnostic kits
7 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET BY GEOGRAPHY
7.1 North America
7.1.1 Key market trends
7.1.2 Competitive scenario
7.1.3 Key growth factors and opportunities
7.1.4 Market size and forecast
7.2 Europe
7.2.1 Key market trends
7.2.2 Competitive scenario
7.2.3 Key growth factors and opportunities
7.2.4 Market size and forecast
7.3 Asia-Pacific
7.3.1 Key market trends
7.3.2 Competitive scenario
7.3.3 Key growth factors and opportunities
7.3.4 Market size and forecast
7.4 LAMEA
7.4.1 Key market trends
7.4.2 Competitive scenario
7.4.3 Key growth factors and opportunities
7.4.4 Market size and forecast
8 COMPANY PROFILES
8.1 Roche Diagnostics
8.1.1 Overview
8.1.2 Company snapshot
8.1.3 Financial performance
8.1.4 Strategic moves and developments
8.1.5 SWOT analysis
8.2 BioMerieux
8.2.1 Overview
8.2.2 Company snapshot
8.2.3 Financial performance
8.2.4 Strategic moves and developments
8.2.5 SWOT analysis
8.3 Hologic, Inc.
8.3.1 Overview
8.3.2 Company snapshot
8.3.3 Financial performance
8.3.4 Strategic moves and developments
8.3.5 SWOT analysis
8.4 Becton Dickinson & Company
8.4.1 Overview
8.4.2 Company snapshot
8.4.3 Financial performance
8.4.4 Strategic moves and developments
8.4.5 SWOT analysis
8.5 Cepheid, Inc.
8.5.1 Overview
8.5.2 Company snapshot
8.5.3 Financial performance
8.5.4 Strategic moves and developments
8.5.5 SWOT analysis
8.6 Danaher Corporation
8.6.1 Overview
8.6.2 Company snapshot
8.6.3 Financial performance
8.6.4 Strategic moves and developments
8.6.5 SWOT analysis
8.7 Affymetrix, Inc.
8.7.1 Overview
8.7.2 Company snapshot
8.7.3 Financial performance
8.7.4 Strategic moves and developments
8.7.5 SWOT analysis
8.8 Alere, Inc.
8.8.1 Overview
8.8.2 Company snapshot
8.8.3 Financial performance
8.8.4 Strategic moves and developments
8.8.5 SWOT analysis
8.9 Abbott Laboratories
8.9.1 Overview
8.9.2 Company snapshot
8.9.3 Financial performance
8.9.4 Strategic moves and developments
8.9.5 SWOT analysis
8.10 DiaSorin
8.10.1 Overview
8.10.2 Company snapshot
8.10.3 Financial performance
8.10.4 Strategic moves and developments
8.10.5 SWOT analysis
LIST OF TABLES
TABLE 1 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MODERATE GROWTH SCENARIO MARKET VOLUME BY GEOGRAPHY, 2020-2025 (MILLION TESTS)
TABLE 3 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING RAPID GROWTH SCENARIO MARKET VOLUME BY GEOGRAPHY, 2020-2025 (MILLION TESTS)
TABLE 5 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 6 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING DIMINISHING GROWTH SCENARIO MARKET VOLUME BY GEOGRAPHY, 2020-2025 (MILLION TESTS)
TABLE 7 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET,REVENUE BY TYPES, 2013-2020 ($ MILLION)
TABLE 8 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET, VOLUME BY TYPES, 2013-2020 (MILLION TESTS)
TABLE 9 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE BY GEOGRAPHY, 2013-2020, ($ MILLION)
TABLE 10 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET VOLUME BY GEOGRAPHY, 2013-2020, (MILLION TESTS)
TABLE 11 GLOBAL CHLAMYDIA TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
TABLE 12 GLOBAL CHLAMYDIA TESTING MARKET VOLUME BY GEOGRAPHY (MILLION TESTS)
TABLE 13 GLOBAL P&S SYPHILIS TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
TABLE 14 GLOBAL P&S SYPHILIS TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
TABLE 15 GLOBAL GONORRHEA TESTING MARKET REVENUE BY GEOGRAPHY($ MILLION)
TABLE 16 GLOBAL GONORRHEA TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
TABLE 17 GLOBAL HERPES SIMPLEX VIRUS (HSV) TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
TABLE 18 GLOBAL HERPES SIMPLEX VIRUS (HSV) TESTING MARKET VOLUME BY GEOGRAPHY (MILLION TESTS)
TABLE 19 GLOBAL HUMAN PAPILLOMA VIRUS (HPV) TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
TABLE 20 GLOBAL HUMAN PAPILLOMA VIRUS (HPV) TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
TABLE 21 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING MARKET REVENUE BY GEOGRAPHY ($ MILLION)
TABLE 22 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
TABLE 23 GLOBAL CHANCROID TESTING MARKET REVENUE BY GEOGRAPHY($ MILLION)
TABLE 24 GLOBAL CHANCROID TESTING MARKET VOLUME BY GEOGRAPHY(MILLION TESTS)
TABLE 25 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE BY LOCATION OF TESTING DEVICES, 2013-2020, ($ MILLION)
TABLE 26 GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE BY LOCATION OF TESTING, 2013-2020, ($ MILLION TESTS)
TABLE 27 NORTH AMERICA VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 ($ MILLION)
TABLE 28 NORTH AMERICA VENEREAL DISEASES DIAGNOSTIC TESTING MARKET VOLUME, BY TYPES, 2013-2020 (MILLION TESTS)
TABLE 29 EUROPE VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 ($ MILLION TESTS)
TABLE 30 EUROPE VENEREAL DISEASES DIAGNOSTIC TESTING MARKET VOLUME, BY TYPES, 2013-2020 (MILLION TESTS)
TABLE 31 ASIA PACIFIC VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 ($ MILLION)
TABLE 32 ASIA PACIFIC VENEREAL DISEASES DIAGNOSTIC TESTING MARKET VOLUME, BY TYPES, 2013-2020 (MILLION TESTS)
TABLE 33 LAMEA VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 ($ MILLION)
TABLE 34 LAMEA VENEREAL DISEASES DIAGNOSTIC TESTING MARKET REVENUE, BY TYPES, 2013-2020 (MILLION TESTS)
TABLE 35 ROCHE DIAGNOSTICS BUSINESS SNAPSHOT
TABLE 36 BIOMERIEUX BUSINESS SNAPSHOT
TABLE 37 HOLOGIC, INC BUSINESS SNAPSHOT
TABLE 38 BECTON DICKINSON & COMPANY BUSINESS SNAPSHOT
TABLE 39 CEPHEID, INC.BUSINESS SNAPSHOT
TABLE 40 DANAHER CORPORATIONBUSINESS SNAPSHOT
TABLE 41 AFFYMETRIX, INC. BUSINESS SNAPSHOT
TABLE 42 ALERE, INC. BUSINESS SNAPSHOT
TABLE 43 ABBOTT LABORATORIES BUSINESS SNAPSHOT
TABLE 44 DIASORIN BUSINESS SNAPSHOT
LIST OF FIGURES
FIG. 1 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020-2025)
FIG. 2 IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020-2025)
FIG. 3 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2025)
FIG. 4 TOP FACTORS IMPACTING GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING (2014-2020) TOP WINNING STRATEGIES IN GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET
FIG. 5 TOP INVESTMENT POCKETS OF GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET
FIG. 6 PORTER’S FIVE FORCE MODEL OF GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET
FIG. 7 VALUE CHAIN ANALYSIS OF GLOBAL VENEREAL DISEASES DIAGNOSTIC TESTING MARKET
FIG. 8 ROCHE DIAGNOSTICS SWOT ANALYSIS
FIG. 9 BIOMERIEUX SWOT ANALYSIS
FIG. 10 HOLOGIC, INC SWOT ANALYSIS
FIG. 11 BECTON DICKINSON & COMPANY SWOT ANALYSIS
FIG. 12 CEPHEID, INC.BUSINESS SWOT ANALYSIS
FIG. 13 DANAHER CORPORATION SWOT ANALYSIS
FIG. 14 AFFYMETRIX, INC. SWOT ANALYSIS
FIG. 15 ALERE, INC. SWOT ANALYSIS
FIG. 16 ABBOTT LABORATORIES SWOT ANALYSIS
FIG. 17 DIASORIN SWOT ANALSIS
FIG. 18 BUSINESS PERFORMANCE OF ROCHE DIAGNOSTICS
FIG. 19 BUSINESS PERFORMANCE OF BIOMERIEUX
FIG. 20 BUSINESS PERFORMANCE OF HOLOGIC, INC
FIG. 21 BUSINESS PERFORMANCE OF BECTON DICKINSON & COMPANY
FIG. 22 BUSINESS PERFORMANCE OF CEPHEID, INC.
FIG. 23 BUSINESS PERFORMANCE OF DANAHER CORPORATION
FIG. 24 BUSINESS PERFORMANCE OF AFFYMETRIX, INC.
FIG. 25 BUSINESS PERFORMANCE OF ALERE, INC
FIG. 26 BUSINESS PERFORMANCE OF ABBOTT LABORATORIES
FIG. 27 BUSINESS PERFORMANCE OF DIASORIN
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
